Niacin therapy in atherosclerosis
CD Meyers, VS Kamanna… - Current opinion in …, 2004 - journals.lww.com
CD Meyers, VS Kamanna, ML Kashyap
Current opinion in lipidology, 2004•journals.lww.comNew data indicate that niacin alters lipoprotein metabolism in novel ways, and mediates
other beneficial nonlipid changes that may be atheroprotective. This information forms the
rationale for the use of niacin in combination with agents possessing complementary
mechanisms of action (eg statins) for cardiovascular risk reduction beyond that observed
with monotherapy. Further research into the specific mechanisms of niacin may identify
additional targets for future drug development.
other beneficial nonlipid changes that may be atheroprotective. This information forms the
rationale for the use of niacin in combination with agents possessing complementary
mechanisms of action (eg statins) for cardiovascular risk reduction beyond that observed
with monotherapy. Further research into the specific mechanisms of niacin may identify
additional targets for future drug development.
Summary
New data indicate that niacin alters lipoprotein metabolism in novel ways, and mediates other beneficial nonlipid changes that may be atheroprotective. This information forms the rationale for the use of niacin in combination with agents possessing complementary mechanisms of action (eg statins) for cardiovascular risk reduction beyond that observed with monotherapy. Further research into the specific mechanisms of niacin may identify additional targets for future drug development.
Lippincott Williams & Wilkins